Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for June, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/20: The Fed In Focus This Week
- PFP 5/20: Will We Touch 1700?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Covidien plc. ( COV - Analyst Report ) is set to report its first-quarter fiscal 2013 results, before the market opens, on Friday, Jan 25. Let’s see how things are shaping up prior to the announcement.
In the last quarter, the international health care product major posted a 2.00% positive earnings surprise, reflecting better-than-expected sales and improved expense control.
Factors to Consider this Past Quarter
Covidien continues to expand both organically as well as inorganically, despite a challenging Med-tech environment. Further, the company remains committed to delivering incremental returns to its investors through dividend hikes and share repurchase programs.
We see opportunities for multiple expansions, based on the strength and diversity of the company's business and its ability to grow on the back of strategic investments and portfolio reshaping initiatives toward high-growth/high-margin businesses. Additionally, the exit of a competitor in the nursing care business has presented opportunities for the company to gain market share in the U.S.
However, we remain concerned regarding product recall-related issues, which might affect its top-line growth. Tough competition as well as acquisition and divestment risks continue to be major headwinds for the company.
Earnings Whispers?
Our proven model does not conclusively show that Covidien is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) (Read: Zacks Earnings ESP: A Better Method) as well as a Zacks Rank of #1, 2 or 3 for this to happen. This is not the case here as you will see below.
Zacks Earnings ESP: The Most Accurate estimate stands at $1.06, while the Zacks Consensus Estimate is also pegged at $1.06. This comes to a difference of 0.00%.
Zacks Rank #3 (Hold): Covidien’s Zacks Rank #3 (Hold) lowers the predictive power of ESP. The Zacks Rank #3 together with 0.00% earnings ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows that these have the right ingredients to post an earnings beat this quarter:
NuVasive Inc. ( NUVA - Snapshot Report ) , Earnings ESP of +72.73% and Zacks Rank #2 (Buy)
Quidel Corp. ( QDEL - Snapshot Report ) ,Earnings ESP of +26.67% and Zacks Rank #2 (Buy)
Hill-Rom Holdings, Inc. ( HRC - Snapshot Report ) , Earnings ESP of +2.27% and Zacks Rank #2 (Buy)
Read the full Analyst Report on COV
Read the full Snapshot Report on NUVA
Read the full Snapshot Report on HRC
Read the full Snapshot Report on QDEL